Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Maruishi Files Midazolam Oral Syrup for Pediatric Use
Maruishi Pharmaceutical said on March 6 that it has filed an oral syrup version of the sedative agent midazolam for pre-anesthetic administration in children in Japan.The company currently markets an injection version of midazolam, Dorumicum. The oral version was developed…
To read the full story
Related Article
- Japan Panel Clears Izervay, Nexletol for Approval; Eylea Biosimilars Edge Ahead Too
September 1, 2025
- Astellas’ Izervay, Otsuka’s Nexletol among New Drugs Up for Japan Panel Review; Eylea Biosimilars Also on Agenda
August 19, 2025
- Maruishi’s Midazolam Designated as Drug for Specific Use
December 26, 2024
BUSINESS
- Celltrion to Lift Shipment Curbs on Japan’s 1st Actemra Biosimilar
November 9, 2026
- AstraZeneca Vows to Back Japanese Innovation with Global Potential
November 9, 2026
- Qol Eyes Biosimilars as Next Growth Pillar after AGs
November 9, 2026
- Nippon Shinyaku Flags Possible IR Data Leak
November 9, 2026
- Espha Debuts NorLevo Generic in Japan
November 9, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…